Fixed-Dose Ibuprofen/Famotidine: A Review of Its Use to Reduce the Risk of Gastric and Duodenal Ulcers in Patients Requiring NSAID Therapy
- 271 Downloads
A fixed-dose combination of the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen and the histamine H2 receptor antagonist famotidine (ibuprofen/famotidine; DUEXIS®) is now available for the symptomatic treatment of arthritic symptoms and to reduce the risk of upper gastrointestinal (GI) ulcers in patients who require ibuprofen therapy. The gastroprotective efficacy of oral ibuprofen/famotidine 800/26.6 mg three times daily in patients requiring NSAID therapy for inflammatory conditions and/or pain was evaluated in two 24-week, well-designed trials (REDUCE-1 and -2). According to the post-adjudication analysis of these studies, ibuprofen/famotidine significantly reduced the life table estimated rate of gastric ulcers (primary endpoint of REDUCE-1) but not upper GI ulcers (i.e. gastric or duodenal ulcers) [primary endpoint of REDUCE-2] compared with ibuprofen alone. When life table estimated rates of secondary endpoints were assessed, significantly fewer recipients of the fixed-dose combination than of ibuprofen alone developed upper GI ulcers or duodenal ulcers in REDUCE-1, whereas the between-group difference in gastric ulcers and duodenal ulcers was considered to be nonsignificant in REDUCE-2 because of hierarchical testing. However, in a prespecified pooled analysis of REDUCE-1 and -2, the rate of upper GI ulcers as well as each of the upper GI ulcer components was significantly lower with ibuprofen/famotidine than with ibuprofen. Ibuprofen/famotidine was generally well tolerated, with a tolerability profile consistent with those established for the individual agents.
KeywordsIbuprofen Clopidogrel Duodenal Ulcer Gastric Ulcer Misoprostol
The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.
Conflict of interest
This document has been written by in-house editorial staff of Adis Publications, who have no conflict of interest.
- 5.Bello AE. DUEXIS® (ibuprofen 800 mg, famotidine 26.6 mg): a new approach to gastroprotection for patients with chronic pain and inflammation who require treatment with a nonsteroidal anti-inflammatory drug. Ther Adv Musculoskel Dis. 2012;4(5):327–39.Google Scholar
- 6.Horizon Pharma USA Inc. DUEXIS (ibuprofen and famotidine) tablets, for oral use: US prescribing information. 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022519s000lbl.pdf. Accessed 1 Jul 2013.
- 7.Bennett A. Horizon scanning: Duexis (ibuprofen/famotidine) receives marketing authorisation for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis [media release]. 8 Mar 2013. http://www.nelm.nhs.uk/en/NeLM-Area/News/2013-March/08/Horizon-Scanning-Duexis-ibuprofenfamotidine-receives-marketing-authorisation-for-the-symptomatic-treatment-of-osteoarthritis-rheumatoid-arthritis-and-ankylosing-spondylitis/.
- 10.Simon TJ, Berger ML, Hoover ME, et al. A dose ranging study of famotidine in prevention of gastroduodenal lesions associated with non-steroidal anti-inflammatory drugs (NSAIDS): results of a U.S. multicentre trial [abstract no. 116]. Am J Gastroenterol. 1994;89(9):1644.Google Scholar
- 11.Tidmarsh G, Rodriguez SB. Famotidine (FAM) administered orally three times daily (tid) produces better gastric acid suppression and control than does twice daily (bid) administration of the same total daily dose [abstract no. T1971]. Gastroenterology. 2009;136(5 Suppl 1):A611–2.Google Scholar
- 16.Miyake K, Ueki N, Suzuki K, et al. Preventive therapy for non-steroidal anti-inflammatory drug-induced ulcers in Japanese patients with rheumatoid arthritis: the current situation and a prospective controlled-study of the preventive effects of lansoprazole or famotidine. Aliment Pharmacol Ther. 2005;21(Suppl 2):67–72.PubMedCrossRefGoogle Scholar
- 17.US FDA Center for Drug Evaluation and Research. Application number 022519Orig1s000: clinical pharmacology and biopharmaceutics review(s). 2011. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022519Orig1s000ClinPharmR.pdf. Accessed 1 Jul 2013.
- 18.US FDA Center for Drug Evaluation and Research. Application number 022519Orig1s000: pharmacology review(s). 2010. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022519Orig1s000PharmR.pdf. Accessed 1 Jul 2013.
- 19.Tidmarsh G, Rodriguez SB. HZT-501, a novel combination of ibuprofen (Ibu) and famotidine (FAM), provides pharmacokinetics comparable to that of commercially available Ibu and FAM in a patient-friendly dosing form: evaluation in healthy and renally-impaired subjects [abstract no. T1974]. Gastroenterology. 2009;136(5 Suppl):A612.Google Scholar
- 20.Grahn A, Jung D, Kramer W, et al. HZT-501, a novel combination tablet of ibuprofen and famotidine, provides pharmacokinetics comparable to European commercially available ibuprofen in a patient-friendly dosing form: evaluation in healthy subjects [abstract no. 82]. Am J Gastroenterol. 2010;105(S1):S31.Google Scholar
- 21.Katoh Y. Impact of the influence of H2 receptor antagonist (famotidine) on the antiplatelet therapy (aspirin and clopidogrel) [abstract no. AS-212]. Am J Cardiol. 2011;107(8 Suppl):79A.Google Scholar
- 24.Laine L, Kivitz AJ, Bello AE, et al. Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers [published erratum appears in Am J Gastroenterol 2012;107(8):1272]. Am J Gastroenterol. 2012;107(3):379–86.PubMedCrossRefGoogle Scholar
- 25.Schiff M, Weinblatt M, Genovese M, et al. Independent predictors for the development of upper gastrointestinal ulcers with a NSAID: results from two large trials of a single-tablet combination of ibuprofen-famotidine vs. ibuprofen alone [abstract no. THU0383]. European League Against Rheumatism 11th Annual Congress, 16–19 Jun 2010, Rome.Google Scholar
- 26.Weinblatt ME, Genovese MC, Kivitz AJ, et al. Efficacy, safety and tolerability of HZT-501, including users of low-dose aspirin, a single-tablet combination of ibuprofen-famotidine: results of two phase 3 trials [abstract no. 945]. Arthritis Rheum. 2010;62(10 Suppl):S391–2.Google Scholar
- 27.Schiff MH, Genovese MC, Bello AE, et al. Efficacy, safety, and tolerability of a single-tablet combination of ibuprofen-famotidine: results in patients who require nonsteroidal anti-inflammatory drugs for osteoarthritis, rheumatoid arthritis, or chronic pain [abstract no. 264 plus poster]. American Academy of Pain Medicine annual meeting, 23–26 Feb 2012, Palm Springs.Google Scholar
- 28.Horizon Pharma Inc. Efficacy and safety study of HZT-501 in subjects requiring nonsteroidal anti-inflammatory drug (NSAID) treatment [ClinicalTrials.gov identifier NCT00450216]. US National Institutes of Health, ClinicalTrials.gov [online]. 2013. http://www.clinicaltrials.gov. Accessed 1 Jul 2013.
- 29.Horizon Pharma Inc. Efficacy and safety study of HZT-501 in reducing the risk of ibuprofen-associated ulcers [ClinicalTrials.gov identifier NCT00450658]. US National Institutes of Health, ClinicalTrials.gov [online]. 2013. http://www.clinicaltrials.gov. Accessed 1 Jul 2013.
- 30.Goldstein JL, Lakhanpal S, Cohen SB, et al. Long term safety of an NSAID with built-in gastroprotection for treatment of pain and inflammation related to oa and ra: comparative results from blinded and open label one year safety trials of a single-tablet combination of ibuprofen-famotidine [abstract no. Mo1215]. Gastroenterology. 2011;140(5 Suppl 1):S585.Google Scholar
- 31.Goldstein J, Lakhanpal S, Cohen S, et al. Decreased NSAID associated treatment emergent dyspepsia and increased patient satisfaction associated with ibuprofen/famotidine combination tablet: SODA results from a 12-month trial [abstract no. 124]. Am J Gastroenterol. 2012;107(Suppl 1):S52–3.Google Scholar
- 33.Chan FK, Abraham NS, Scheiman JM, et al. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Am J Gastroenterol. 2008;103(11):2908–18.PubMedCrossRefGoogle Scholar
- 35.US FDA. Drug safety communications. 2011 and 2012. http://www.fda.gov/Drugs/DrugSafety/ucm199082.htm. Accessed 1 Jul 2013.
- 40.US FDA Center for Drug Evaluation and Research. Application number 022519Orig1s000: medical review(s). 2011. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022519Orig1s000MedR.pdf. Accessed 1 Jul 2013.